http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 04 Feb 2026 11:45:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Press+Releases/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html <p align="justify">Strasbourg, France, February 4, 2026, 5:45 p.m. CET –<b> Transgene (Euronext Paris: TNG)</b> a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today</b> <b>announces its financial reporting and Annual shareholders’ meeting dates for 2026:</b></p> <p><b>March 24, 2026:</b>               2025 Fiscal Year Results</p> <p><b>April 29, 2026:</b>                 First Quarter 2026 Financial Results</p> <p><b>May 13, 2026:</b>                   Annual Shareholders’ Meeting</p> <p><b>September 24, 2026:</b>       First Half 2026 Financial Results </p> <p align="justify"><b>November 9, 2026:</b>  http://www.streetinsider.com/Globe+Newswire/Transgene+Announces+Financial+Calendar+for+2026/25945206.html Wed, 04 Feb 2026 11:45:00 -0500 A.04051458 A.26800952 O.00325833 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Press+Releases/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG http://www.streetinsider.com/Globe+Newswire/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html <p align="justify"><b>Strasbourg, France, July 9, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), </b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today <b>announced the appointment of Emmanuelle Quilès as an independent Director to its Board of Directors</b>. She succeeds<b> Philippe Archinard, </b>who is retiring from the Board.</p> <p align="justify">Emmanuelle Quilès brings more than 25 years of experience in strategic leadership roles across the global pharmaceutical industry. Until recently, Emmanuelle Quilès served as Worldwide Vice President for Cardiovascular, Metabolism and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson &amp; Johnson).</p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/Transgene+Appoints+Seasoned+Industry+Executive+Emmanuelle+Quil%C3%A8s+to+Board+of+Directors+as+Independent+Director/25032727.html Wed, 09 Jul 2025 11:45:00 -0500 A.04051458 A.26800952 A.31413859 O.00325833 O.00357198 O.00711722 O.06903042 TNG